Yale School of Medicine - Internal Medicine

New research links sleep-related leg movements to a higher risk of diabetes.

New research reveals GLP-1 receptor agonists may protect the liver from alcohol damage while increasing blood alcohol levels, prompting further human studies.

Yale researchers reveal how essential coenzyme A is imported into mitochondria, shedding light on its role in metabolic diseases and potential treatments.

Researchers unveil Bobcat339, a targeted molecule that selectively eliminates pathogenic macrophages.

A study reveals that APOE e4 carriers with atrial fibrillation on Eliquis face increased intracranial hemorrhage risk, highlighting critical genetic implications.

Yale researchers demonstrate that hands-on culinary medicine training significantly boosts nutrition knowledge and confidence among medical residents, enhancing patient care.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

A new position paper established an evidence-based definition for systemic corticosteroid (SCS) duration in individuals with atopic dermatitis.

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.

Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.

Cafraglutide was effective with less frequent dosing than currently available medications that target GLP-1.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

In a new study, Yale researchers develop a method that has the potential to cure cystic fibrosis prior to birth.

A clinician performing an echocardiogram of a patient's heart

The Yale Biomedical Imaging Institute will drive transformative advancements in both basic science and clinical translation.

Yale researchers developed an AI model that illuminates critical details about—and possible treatments for—idiopathic pulmonary fibrosis. It could do so for many other diseases.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.